Document is current
Any future updates will be listed below
-
Authors
Thomas, Hannah M. T.
Hippe, Daniel S.
Forouzannezhad, Parisa
Sasidharan, Balu Krishna
Kinahan, Paul E.
Miyaoka, Robert S.
Vesselle, Hubert J.
Rengan, Ramesh
Zeng, Jing
Bowen, Stephen R.
-
Funding
Funding for this research was provided by:
National Institutes of Health (R01CA204301)
National Institutes of Health (R01CA204301)
National Institutes of Health (R01CA204301)
National Institutes of Health (R01CA258997)
National Institutes of Health (R01CA204301)
National Institutes of Health (R01CA204301)
National Institutes of Health (R01CA204301)
National Institutes of Health (R01CA204301)
National Institutes of Health (R01CA204301)
Biostatistics Shared Resource of the Fred Hutch/University of Washington Cancer Consortium (P30 CA015704)
- License Information
-
More Information
Article History
Received: 6 June 2022
Accepted: 23 August 2022
First Online: 1 September 2022
Declarations
:
: The study was reviewed and approved by the University of Washington/Fred Hutchinson Cancer Centre institutional review board in accordance with the Helsinki Declaration. All patients included have consented to the study.
: All authors consent for manuscript to be published in Discover Oncology, if accepted.
: JZ and RR serve as consultants to Astrazeneca. PEK declares support from GE Healthcare and is co-founder of PET/X, LLC. RSM and HJV declare support from Philips Healthcare and serve as consultants for MIM Software. DSH declares support from GE Healthcare, Philips Healthcare, and Canon Medical Systems USA.
